|
Arecor Therapeutics PLC on Monday highlighted the advancement of its lead product AT278, which is ultra-rapid-acting insulin, as it reported annual revenue growth. The Cambridgeshire, England-based biopharmaceutical company said it swung to a pretax profit of £994,000 in 2025, from a loss of £5.1 million. Revenue rose 4.3% to £1.7 million from £1.6 million. Notably, other operating income surged to £5.5 million, including a £5.0 million gain on the sale of royalty rights, compared to other operating income of £267,000 in 2024, which had no gain on sale of royalty rights. Research & development costs came down 11% to £2.7 million in 2025 from £3.0 million in 2024. General & administrative expenses reduced 4.4% to £3.2 million from £3.3 million. Arecor Therapeutics emphasised that its lead product, AT278, which is ultra-concentrated, ultra-rapid-acting insulin, advanced across product development and commercial partnering. It noted that phase 2 trial-enabling work was progressing well, with a phase 2 clinical trial expected to start during the second half of 2026. Chief Executive Officer Sarah Howell said: ‘Arecor is actively addressing high growth, multi-billion-dollar markets through our focus on two core therapeutic areas, diabetes and oral delivery of peptides. These are both areas of unmet patient need which have the potential to generate significant value for shareholders.’ She added: ‘The current focus for the board is to secure the best possible deal to take AT278 into phase 2 in the second half of 2026 and to advance our oral peptide delivery platform. We are doing this with careful financial management to ensure we have sufficient time and resource to achieve our strategic objectives.’ Looking ahead, Chair Andrew Richards said: ‘Positive negotiations are in progress on a broader co-development and commercialisation partnership for the phase 2 trial and beyond and are a current key focus for management. ‘The board has a high level of conviction in Arecor’s focussed strategy. We remain excited by the positive impact that we can have for outcomes for people living with diabetes and other cardiometabolic diseases, through both the combination of our ultra-rapid-acting and ultra-concentrated AT278 insulin with increasingly accurate AID systems worn for extended periods of time, and also our developments in the exciting field of oral peptide delivery.’ Arecor shares rose 4.2% to 67.18 pence each on Monday afternoon in London. Copyright 2026 Alliance News Ltd. All Rights Reserved.
|
